Dengue: all 284 studies

Page 1 of 3. Open to participants first (44), then studies with results posted, then the rest; newest registration first within each.

• Phase I Study of VLPDEN-02 Dengue Vaccine in Healthy AdultsNot yet recruitingNCT07831473Phase 1
• Investigating and Modelling the Natural History of Dengue in Hospitalised Patients to Improve Future ResearchNot yet recruitingNCT07799168
• Phase 1 Challenge Study Using rDEN2delta30-7169 to Evaluate Host-Pathogen Interactions in Primary, Homotypic, and Heterotypic Dengue Virus InfectionRecruitingNCT07706686Phase 1
• Smart Analysis and Decision-Making for Emerging Infectious DiseasesEnrolling by invitationNCT07678619Not applicable
• Gut Leakage' in DengueRecruitingNCT07602920
• Effects Of A Rehabilitation Protocol On Muscle Strength, Muscle Fatigue And Postural Control In Post-Dengue And Chikungunya PatientsNot yet recruitingNCT07600879Not applicable
• A Study of CP-COV03 Compared With Placebo in Participants With Dengue (Part 1) and Dengue-like Illness (Part 2)RecruitingNCT07576868Phase 2/3
• Therapeutics for Moderate and Severe DengueNot yet recruitingNCT07543458Phase 3
• Xpert® Tropical Fever Test on GeneXpert® Edge X SystemEnrolling by invitationNCT07520279
• International Registry of Dengue Infection in Congenital Bleeding Disorders (DengueCBDR)RecruitingNCT07409857
• Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health PerspectiveRecruitingNCT07358910
• Dengue - Sample Collection Study PakistanNot yet recruitingNCT07203183
• To Assess the Efficacy of Carica Papaya Leaf Extract in Improving Platelet Counts Among Pediatric Patients With Dengue-associated ThrombocytopeniaEnrolling by invitationNCT07172100Phase 2
• Prospective Clinical Registry for Evaluation of Exanthematous Infections and CoinfectionsNot yet recruitingNCT07112846
• Immune Responses to Dengue and SepsisRecruitingNCT07040202
• Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative)RecruitingNCT07016321Phase 2/3
• Risk Factors for Hospitalization and Transfusion Criteria in Patients With Dengue Virus InfectionRecruitingNCT07007585
• Effectiveness Evaluation of the "Mosquito-Free Campus" Initiative on Dengue Fever Prevention and Control: A Cluster Randomized Controlled TrialNot yet recruitingNCT07002021Not applicable
• Molecular and Cellular Basis of Severe Forms of Dengue in Sickle Cell PatientsRecruitingNCT07000747
• Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years.Not yet recruitingNCT06973772Phase 3
• Clinical Trial Evaluating Safety and Efficacy of Resomelagon on Dengue Infection (RESOVIR-2)RecruitingNCT06917001Phase 2
• Safety, Virological and Immunological Assessment of the Controlled Dengue Human Infection Model in Dengue-Immune Participants in Thailand (DHIT-Immune)Not yet recruitingNCT06908018Early Phase 1
• Impact of IIT-SIT on Dengue ClustersRecruitingNCT06894901Not applicable
• Butantan-DV Vaccine in Elderly Populations (DEN-04-IB)RecruitingNCT06891950Phase 3
• Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-borne DiseasesNot yet recruitingNCT06859619Not applicable
• A Study in Children and Teenagers to Learn if a TDV Dengue Vaccination Lowers the Chance of Hospital Stays for DengueRecruitingNCT06843226
• Characterisation of Dengue Vaccine-induced Specific Immunity in Vaccinees With and Without Prior Exposure to Flavivirus Infections or VaccinationRecruitingNCT06776692
• Innovative Multidisciplinary Strategies for Combating Severe DengueRecruitingNCT06751836
• Efficacy of Montelukast in Preventing Transaminase Elevation in Adult Dengue PatientsRecruitingNCT06747130Phase 2/3
• A Study of 2 Doses of Tetravalent Dengue Vaccine (TDV) in Infants and ToddlersRecruitingNCT06665035Phase 3
• Adaptive Dengue Antiviral Platform TrialRecruitingNCT06551844Phase 2
• Dengue Virus Infection Amongst Patients With Acute Febrile IllnessRecruitingNCT06255509
• Prevalence of Hyponatremia in Dengue Infected Patients: Relationship With Systemic Inflammation.RecruitingNCT06109532
• Role of Vitamin D in Prevention of Dengue Haemorrhagic Fever and Dengue Shock SyndromeRecruitingNCT06071481Phase 2
• A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue FeverRecruitingNCT06006559Phase 2
• A Dengue Sero-prevalence Study in the Metropolitan Area of Buenos AiresRecruitingNCT05919277
• Effectiveness of iDEAL in Improving the Knowledge, Attitude, Practice, Environmental Cleanliness Index and Dengue IndexNot yet recruitingNCT05863026Not applicable
• Study of Dengue in Patients With Autoimmune Diseases During the Epidemics of 2020 and 2021 in Reunion IslandNot yet recruitingNCT05852977
• Safety, Virological and Immunological Assessment of Live Attenuated Dengue Serotype 2 rDEN2delta30-7169.Not yet recruitingNCT05476757Early Phase 1
• Metabolic and Infectious Diseases in La Réunion (the REUNION Population-based Study)RecruitingNCT05400824
• Dengue Vaccine Strategy in Children Aged 9 to 17 Years in the French CaribbeanRecruitingNCT04839757
• NT-proBNP and Troponin I in Dengue ChildrenRecruitingNCT04837430
• Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE)RecruitingNCT04597437Phase 2
• Dengvaxia US Pregnancy RegistryRecruitingNCT04486638
• Immunogenicity of an Intradermal Qdenga Vaccine Among Healthy VolunteersCompletedNCT06837116Early Phase 1Results posted
• Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan - DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181 - 002)CompletedNCT05710224Phase 2Results posted
• Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003)CompletedNCT05507450Phase 2Results posted
• Study of AT-752 in Patients With Dengue InfectionTerminatedNCT05466240Phase 2Results posted
• Dengue 4 Human Infection Model (Dengue CVD 11000; DHIM-4)CompletedNCT05268302Phase 1Results posted
• A Study of JNJ-64281802 for the Prevention of Dengue InfectionTerminatedNCT05201794Phase 2Results posted
• An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 ChallengeCompletedNCT05048875Phase 2Results posted
• A Study of JNJ-64281802 in Participants With Confirmed Dengue FeverTerminatedNCT04906980Phase 2Results posted
• ADVP005; Dengue CVD 12000 - Dengue-1-Virus Live Virus Human Challenge (DENV-1-LVHC)CompletedNCT04786457Phase 1Results posted
• Sylvatic Transmission of Zika, Dengue, and Chikungunya Viruses in Thailand and CambodiaCompletedNCT04434846Results posted
• Quantifying the Epidemiological Impact of Targeted Indoor Residual Spraying on Aedes-borne DiseasesCompletedNCT04343521Not applicableResults posted
• Immunogenicity and Safety of Dengue Tetravalent Vaccine (TDV) and Recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) in Participants Aged ≥9 to <15 YearsCompletedNCT04313244Phase 3Results posted
• Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster DoseCompletedNCT03999996Phase 3Results posted
• Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) at the End of Shelf Life in Healthy AdultsCompletedNCT03771963Phase 3Results posted
• Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune AdultsCompletedNCT03746015Phase 2Results posted
• Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Co-administered With an Hepatitis A Virus VaccineCompletedNCT03525119Phase 3Results posted
• Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for DengueCompletedNCT03423173Phase 3Results posted
• Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in AdultsCompletedNCT03342898Phase 3Results posted
• Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) in Adolescents in Non-Endemic Area(s)CompletedNCT03341637Phase 3Results posted
• Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil®CompletedNCT02993757Phase 3Results posted
• Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy SubjectsTerminatedNCT02992418Phase 3Results posted
• Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix®CompletedNCT02979535Phase 3Results posted
• Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy ChildrenCompletedNCT02948829Phase 2Results posted
• Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose ScheduleCompletedNCT02824198Phase 2Results posted
• GLS-5700 in Dengue Virus-Naïve AdultsCompletedNCT02809443Phase 1Results posted
• This Study Will Describe the Burden of DENgue Fever Virus (DENV) Illness Among Household Members Aged 6 Months to 50 Years of Selected Communities in Latin America and Southeast AsiaTerminatedNCT02766088Not applicableResults posted
• Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive AdultsCompletedNCT02741128Phase 2Results posted
• Safety and Immunogenicity of the Dengue Virus Vaccine TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, BangladeshCompletedNCT02678455Phase 2Results posted
• Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of AgeCompletedNCT02628444Phase 2Results posted
• Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose ScheduleCompletedNCT02623725Phase 2Results posted
• A Cohort Study to Determine the Incidence of Dengue Fever and to Build Capacity for Dengue Vaccine Trials in Dengue-endemic Regions of South AsiaCompletedNCT02570152Not applicableResults posted
• Safety and Immunogenicity With Two Different Serotype 2 Potencies of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Adults in SingaporeCompletedNCT02425098Phase 2Results posted
• A Prospective, Open Label, Treatment Use Study of Patient Safety Following Transfusion of INTERCEPT Platelet ComponentsCompletedNCT02305732Results posted
• Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy ParticipantsCompletedNCT02302066Phase 2Results posted
• Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV)CompletedNCT02193087Phase 2Results posted
• Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy StudyCompletedNCT01983553Results posted
• Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue VaccineCompletedNCT01943825Phase 2Results posted
• A Phase I/II Trial of a Tetravalent Live Attenuated DEN Vaccine in Flavivirus Antibody Naive ChildrenCompletedNCT01843621Phase 1/2Results posted
• An Epidemiological Surveillance Study to Evaluate the Incidence of Dengue in BrazilTerminatedNCT01751139Not applicableResults posted
• Impact of SC vs IM Administration of DENVax (TDV) on Safety and ImmunogenicityCompletedNCT01728792Phase 1Results posted
• A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy AdultsCompletedNCT01666652Phase 1Results posted
• Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in IndiaCompletedNCT01550289Phase 2Results posted
• A Comparison of the Safety and Immunogenicity of Various Schedules of Dengue Vaccine in Healthy Adult VolunteersCompletedNCT01542632Phase 1Results posted
• Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 YearsCompletedNCT01511250Phase 2Results posted
• Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever VaccineCompletedNCT01488890Phase 2Results posted
• Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy ToddlersCompletedNCT01436396Phase 3Results posted
• Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy ToddlersCompletedNCT01411241Phase 3Results posted
• Study to Evaluate the Incidence, Clinical Characteristics and Economic Burden of Dengue in Brazilian ChildrenCompletedNCT01391819Not applicableResults posted
• Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin AmericaCompletedNCT01374516Phase 3Results posted
• Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in AsiaCompletedNCT01373281Phase 3Results posted
• Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in MalaysiaCompletedNCT01254422Phase 3Results posted
• Safety and Immunogenicity Study to Assess TDV, a Live Attenuated Tetravalent Vaccine for Prevention of Dengue FeverCompletedNCT01224639Phase 1Results posted
• Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South AmericaCompletedNCT01187433Phase 2Results posted
• Study of a Tetravalent Dengue Vaccine in Healthy Adults in AustraliaCompletedNCT01134263Phase 3Results posted
• Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin AmericaCompletedNCT00993447Phase 2Results posted
• Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in SingaporeCompletedNCT00880893Phase 2Results posted

← Dengue overview